PMID: 9625576Jun 13, 1998Paper

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia

American Journal of Hematology
M MontilloF Ferrara


Thirty-eight patients with primary resistant or relapsing acute myeloid leukemia (AML) were treated with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). Median age was 41 (range 11-70). Sixteen patients had AML that was primary resistant to induction treatment, while 22 were relapsed, 11 after autologous bone marrow transplant (AuBMT), 8 less than 6 months from complete remission (CR) achievement, and 3 were second relapse from chemotherapy alone. Overall, 21 of 38 patients (55%) obtained CR. Age, sex, length of CR, and interval between autoBMT and FLAG administration did not significantly influence the CR rate. On the contrary, a normal karyotype at diagnosis was significantly related to a better outcome. There were 4 induction deaths (10%), due to fungal infection in 2 patients and hemorrhagic complications in the remaining two. All patients experienced profound cytopenia. Median time to neutrophil (>500/microl) recovery was 21 days, while a platelet count >20,000/microl was reached after 23 days. The median period of hospitalization was 31 days. The nonhematological toxicity was mild, mainly consisting of mucositis. There were 17 documented infections and 17 episodes of fever of unknown origin. Foll...Continue Reading


Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S AmadoriF Mandelli
Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J KeatingE J Freireich
Jul 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R H HerzigG P Herzig
Jan 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V GandhiW Plunkett
Dec 13, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B LöwenbergW L van Putten

❮ Previous
Next ❯


Dec 2, 2014·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Alaa Fadhil AlwanAli Muhammad Jawad
Apr 21, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·H C WilsonR A Hughes
Apr 12, 2003·Leukemia & Lymphoma·Tadeusz Robak
Sep 1, 2009·Clinical Lymphoma & Myeloma·Mike G MartinCamille N Abboud
Apr 10, 2013·Cancer Treatment Reviews·Pawel Robak, Tadeusz Robak
Jul 8, 2009·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ewa Lech-MarandaTadeusz Robak
May 2, 2015·Journal of Clinical Medicine·Nestor R RamosChristopher S Hourigan
Jan 5, 2002·Hematological Oncology·R J Frewin, S A Johnson
Jul 13, 2002·Expert Review of Anticancer Therapy·Slobodan Stanisic, Matt Kalaycio
Jan 15, 2019·Current Opinion in Hematology·Alice S Mims, William Blum
Apr 25, 2018·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ali McBrideKurt Weibel
Mar 6, 2003·British Journal of Cancer·P KaaijkA J P Veerman
Oct 6, 2006·Expert Review of Anticancer Therapy·Marco MontilloAlessandra Tedeschi
Jun 9, 2014·Cancer Chemotherapy and Pharmacology·Bingnan ZhangNikolai Podoltsev
Oct 13, 2006·Current Opinion in Infectious Diseases·M Potter

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.